1Y Close · As of Aug 26, 2026
Samsung Biologics operates in the Pharmaceuticals sector.
Legal name: SAMSUNG BIOLOGICS CO.,LTD.
In fiscal year 2025, Samsung Biologics (207940) reported revenue of 4.56 trillion KRW, up 0.2% from 4.55 trillion KRW a year earlier.
Operating profit was 2.07 trillion KRW and net income was 1.78 trillion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 74.02 trillion KRW, with a P/B of 9.93.
These figures can be verified in the DART filing (receipt no. 20260515001658).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 4.6T | 2.1T | 1.8T |
| 2024 | 4.5T | 1.3T | 1.1T |
| 2023 | 3.7T | 1.1T | 857.7B |
| 2022 | 3.0T | 983.6B | 798.1B |
| 2021 | 1.6T | 537.3B | 393.6B |
Recent Filings
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Material Event Report (Capital Increase Decision)
Semi-Annual Report (2026.06)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-28 | [기재정정]주요사항보고서(타법인주식및출자증권양수결정) |
| 2026-08-28 | Material Event Report (Capital Increase Decision) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-14 | Payment and Dispute Resolution |
| 2026-08-06 | Officer/Major Shareholder Ownership Report |